Patrick M Bennett, MD
Urology · Novato
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 8
- 1 carrier
- Offices
- 2
- Since medical school
- 37 years
- University of California, San Francisco School of Medicine, 1989
Offices
2 locations · Marin Community Clinic · Regents Univ of California UCSF
Hospitals listed: Marinhealth Medical Center · Novato Community Hospital · Sonoma Valley Hospital. That is not proof they admit you there this week.
Plans that list them
8 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bennett’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G78346 · Current
Licensed to practise in California · since 1994 · expires 2028-02-29 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Marin Health Ventures, LLC dba Marin Specialty Surgery CenterAmbulatory Surgery Center · Greenbrae, CA6.6% owner since 2008 · accredited by AAAHCAccreditation Renewed4 inspections, 2 with deficiencies · last 2025-11-06: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Urology - Urology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sonoma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.63 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 35 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.6 · 345 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.94) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.38) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.58 to 4.03) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.45) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 540 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 60 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.5 · 47 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.2 to 17.9) · 486 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 83 cases | No different | Jan 2024 – Dec 2024 |
What patients said (164 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 88% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 84% |
| Doctors "always" listened carefully | 88% |
| Doctors "always" treated them with courtesy and respect | 92% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$324,204
Medicare paid this office $324,204 for 1,225 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 629 | $84,214 | $103 |
| Diagnostic exam of bladder and urethra using an endoscope | 177 | $48,014 | $212 |
| New patient visit (45+ min) | 281 | $37,610 | $134 |
| Short return visit (20+ min) | 375 | $31,742 | $72 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 34 | $20,962 | $617 |
See all 23 services
| Return visit (30+ min) | 629 | $84,214 | $103 |
| Diagnostic exam of bladder and urethra using an endoscope | 177 | $48,014 | $212 |
| New patient visit (45+ min) | 281 | $37,610 | $134 |
| Short return visit (20+ min) | 375 | $31,742 | $72 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 34 | $20,962 | $617 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $11,071 | None |
| Crushing of stone of ureter with insertion of stent using an endoscope | 22 | $7,833 | $326 |
| Limited ultrasound scan of pelvis | 137 | $5,728 | $41 |
| Telephone medical discussion with physician, 11-20 minutes | 69 | $5,690 | $76 |
| Repair of groin hernia (5 years or older) | 12 | $5,320 | $443 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 11 | $4,280 | $357 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,158 | $109 |
| Insertion of stent in ureter using an endoscope | 28 | $3,312 | $114 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $3,091 | $238 |
| New patient visit (30+ min) | 31 | $2,947 | $95 |
| Insertion of lower leg neurostimulator electrode | 11 | $1,978 | $116 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 133 | $1,908 | $14 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,670 | $104 |
| Simple insertion of temporary bladder tube | 24 | $1,637 | $53 |
| Insertion of tube into ureter using an endoscope through bladder area | 19 | $1,228 | $61 |
| Insertion of temporary bladder tube | 18 | $702 | $39 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $666 | $33 |
| Short return visit | 12 | $629 | $52 |
Procedures Medicare counted
| Hernia repair - groin (open) | 1-10 | None |
| Hernia repair (minimally invasive) | 1-10 | None |
| Prostate resection | 53 | More than 97% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Diagnostic exam of bladder and urethra using an endoscope | 181 | 171 | 183 | 202 | 225 | 226 |
| Simple change of bladder tube | 69 | 79 | 81 | 36 | 50 | – |
| Insertion of temporary bladder tube | 76 | 37 | 48 | 42 | 26 | 18 |
| Simple insertion of temporary bladder tube | 43 | 33 | 37 | 28 | 35 | 31 |
| Complicated insertion of bladder tube | 49 | 15 | 112 | 31 | – | – |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 30 | 24 | 41 | 28 | 32 | 34 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,225 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 17% · Women 17% · Also on Medicaid 9% · Health risk score 1.15. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 68% · Coronary heart disease 36% · Cancer 27% · Atrial fibrillation 23% · Chronic kidney disease 21% · Diabetes 16% · Depression 15% · Heart failure 13% · Stroke 12% · COPD 8% · Dementia 6%.
The office billed $2,105,124, Medicare allowed $442,104 and paid $324,204; for 3,604 services of 72 kinds; $15,335 of it was for drugs given in the office and $308,868 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,225 | 3,604 | 77 | 1.15 | $2,105,124 | $324,204 |
| 2023 | 1,244 | 4,357 | 78 | 1.12 | $2,132,271 | $323,705 |
| 2022 | 1,142 | 4,665 | 77 | 1.08 | $1,983,786 | $314,058 |
| 2021 | 1,051 | 6,579 | 77 | 1.11 | $2,323,352 | $339,367 |
| 2020 | 943 | 6,850 | 76 | 1.18 | $2,080,958 | $285,553 |
| 2019 | 1,056 | 6,000 | 76 | 1.22 | $2,266,374 | $298,163 |
| 2018 | 1,175 | 7,206 | 76 | 1.15 | $966,310 | $335,874 |
| 2017 | 1,088 | 5,964 | 76 | 1.08 | $942,610 | $322,617 |
| 2016 | 957 | 4,498 | 76 | 1.04 | $828,431 | $294,179 |
| 2015 | 961 | 6,627 | 76 | 1.11 | $1,275,555 | $315,105 |
| 2014 | 1,050 | 4,133 | 76 | 1.02 | $1,307,881 | $324,898 |
| 2013 | 1,084 | 4,240 | 76 | 1.07 | $1,198,521 | $314,942 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Return visit (30+ min) | 559 | $77,938 | $106 |
| Diagnostic exam of bladder and urethra using an endoscope | 174 | $49,369 | $219 |
| New patient visit (45+ min) | 373 | $48,579 | $130 |
| Short return visit (20+ min) | 377 | $32,377 | $74 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 32 | $19,531 | $610 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $11,053 | None |
| Limited ultrasound scan of pelvis | 147 | $6,109 | $40 |
| Repair of groin hernia (5 years or older) | 12 | $5,345 | $445 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $4,639 | $331 |
| Simple change of bladder tube | 12 | $4,315 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,190 | $110 |
| New patient visit (30+ min) | 44 | $3,817 | $87 |
| Urinalysis, manual test | 672 | $3,059 | $3 |
| Insertion of stent in ureter using an endoscope | 21 | $3,010 | $120 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,520 | $210 |
| Simple insertion of temporary bladder tube | 27 | $2,073 | $59 |
| Instillation of anti-cancer drug into bladder | 13 | $1,892 | $73 |
| Long return visit (40+ min) | 12 | $1,818 | $151 |
| Insertion of temporary bladder tube | 26 | $988 | $38 |
| Aspiration of bladder with insertion of bladder tube to skin | 14 | $844 | $60 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $635 | $32 |
| Short return visit | 12 | $536 | $45 |
2022: 21 services
| Return visit (30+ min) | 504 | $75,715 | $116 |
| New patient visit (45+ min) | 373 | $56,799 | $152 |
| Diagnostic exam of bladder and urethra using an endoscope | 166 | $43,572 | $216 |
| Short return visit (20+ min) | 314 | $29,654 | $81 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 28 | $16,730 | $597 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $7,193 | None |
| Limited ultrasound scan of pelvis | 163 | $6,431 | $38 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $4,269 | $328 |
| Destruction and/or removal of large growth of bladder using an endoscope | 12 | $4,212 | $324 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 16 | $4,059 | $214 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,187 | $110 |
| Urinalysis, manual test | 714 | $3,114 | $3 |
| Insertion of stent in ureter using an endoscope | 20 | $2,938 | $122 |
| Complicated insertion of bladder tube | 16 | $2,935 | $95 |
| Simple change of bladder tube | 12 | $2,876 | $80 |
| New patient visit (30+ min) | 27 | $2,761 | $102 |
| Simple insertion of temporary bladder tube | 24 | $1,561 | $56 |
| Insertion of temporary bladder tube | 40 | $1,310 | $31 |
| Insertion of tube into ureter using an endoscope through bladder area | 16 | $926 | $58 |
| Injection of drug or substance under skin or into muscle | 11 | $172 | $13 |
| Ultrasound measurement of bladder capacity after voiding | 13 | $138 | $11 |
2021: 25 services
| Return visit (30+ min) | 459 | $63,598 | $107 |
| New patient visit (45+ min) | 317 | $43,013 | $136 |
| Diagnostic exam of bladder and urethra using an endoscope | 148 | $38,849 | $212 |
| Short return visit (20+ min) | 308 | $25,736 | $71 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 41 | $25,343 | $618 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $20,691 | None |
| Complicated insertion of bladder tube | 30 | $15,610 | $139 |
| Simple change of bladder tube | 19 | $6,857 | $85 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 15 | $6,188 | $364 |
| Limited ultrasound scan of pelvis | 135 | $5,765 | $40 |
| Instillation of anti-cancer drug into bladder | 11 | $4,476 | $83 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $3,814 | $238 |
| New patient visit (30+ min) | 39 | $3,591 | $92 |
| Insertion of stent in ureter using an endoscope | 24 | $3,584 | $124 |
| Urinalysis, manual test | 588 | $2,788 | $3 |
| Simple insertion of temporary bladder tube | 22 | $2,286 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,212 | $116 |
| Insertion of temporary bladder tube | 39 | $1,943 | $40 |
| Long return visit (40+ min) | 12 | $1,744 | $125 |
| Short return visit | 23 | $1,025 | $39 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $958 | $27 |
| Insertion of tube into ureter using an endoscope through bladder area | 11 | $836 | $70 |
| Aspiration of bladder with insertion of bladder tube to skin | 11 | $752 | $68 |
| Injection of drug or substance under skin or into muscle | 14 | $488 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 34 | $374 | $10 |
2020: 26 services
| Return visit (30+ min) | 369 | $38,369 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 138 | $32,029 | $187 |
| Short return visit (20+ min) | 415 | $30,586 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $29,485 | None |
| New patient visit (45+ min) | 214 | $26,339 | $123 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 24 | $15,255 | $636 |
| Botox | 17 | $11,488 | None |
| Exam with injections of chemical for destruction of bladder using an endoscope | 19 | $6,848 | $326 |
| Simple change of bladder tube | 22 | $6,679 | $85 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $4,527 | $348 |
| Limited ultrasound scan of pelvis | 111 | $4,309 | $38 |
| New patient visit (30+ min) | 44 | $3,876 | $88 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 11 | $3,343 | $304 |
| Long return visit (40+ min) | 23 | $3,119 | $125 |
| Instillation of anti-cancer drug into bladder | 13 | $2,443 | $74 |
| Urinalysis, manual test | 481 | $2,406 | $3 |
| New patient visit (60+ min) | 13 | $2,278 | $175 |
| Insertion of device into abdomen with pressure and urine flow rate study | 13 | $2,064 | $159 |
| Simple insertion of temporary bladder tube | 23 | $1,807 | $55 |
| Complicated insertion of bladder tube | 13 | $1,615 | $108 |
| Short return visit | 38 | $1,600 | $38 |
| Insertion of temporary bladder tube | 35 | $1,298 | $35 |
| Biopsy of bladder using an endoscope | 13 | $1,050 | $75 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $731 | $30 |
| Injection of drug or substance under skin or into muscle | 36 | $574 | $11 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 14 | $435 | $31 |
2019: 31 services
| Return visit (30+ min) | 359 | $37,838 | $90 |
| Diagnostic exam of bladder and urethra using an endoscope | 153 | $30,148 | $167 |
| Short return visit (20+ min) | 355 | $27,226 | $62 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $23,614 | None |
| New patient visit (45+ min) | 148 | $20,512 | $139 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 30 | $18,786 | $626 |
| New patient visit (30+ min) | 144 | $12,595 | $87 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 21 | $8,091 | $352 |
| Limited ultrasound scan of pelvis | 159 | $6,571 | $39 |
| Simple change of bladder tube | 15 | $5,885 | $85 |
| Complicated insertion of bladder tube | 23 | $5,588 | $114 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 15 | $4,971 | $311 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 131 | $4,807 | $20 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $4,713 | $295 |
| Destruction and/or removal of large growth of bladder using an endoscope | 11 | $3,670 | $334 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 15 | $3,430 | $202 |
| Insertion of temporary bladder tube | 60 | $2,929 | $39 |
| Insertion of device into abdomen with pressure and urine flow rate study | 22 | $2,909 | $132 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $2,698 | $245 |
| Simple insertion of temporary bladder tube | 27 | $2,411 | $56 |
| Urinalysis, manual test | 468 | $2,252 | $3 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,068 | $115 |
| Insertion of stent in ureter using an endoscope | 13 | $1,634 | $126 |
| Biopsy of bladder using an endoscope | 15 | $1,615 | $85 |
| Short return visit | 22 | $894 | $39 |
| Ultrasound measurement of bladder capacity after voiding | 67 | $831 | $11 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 26 | $787 | $30 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $500 | $28 |
| Injection of drug or substance under skin or into muscle | 11 | $212 | $14 |
| Electronic assessment of bladder emptying | 13 | $84 | $6 |
| Automated urinalysis test | 11 | $27 | $2 |
2018: 34 services
| New patient visit (45+ min) | 304 | $39,583 | $130 |
| Return visit (30+ min) | 351 | $35,491 | $87 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $32,233 | None |
| Short return visit (20+ min) | 421 | $30,691 | $59 |
| Diagnostic exam of bladder and urethra using an endoscope | 168 | $27,717 | $143 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 22 | $14,169 | $644 |
| Limited ultrasound scan of pelvis | 205 | $9,455 | $43 |
| New patient visit (30+ min) | 92 | $7,947 | $86 |
| Botox | 14 | $7,704 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 170 | $6,675 | $20 |
| Insertion of temporary bladder tube | 108 | $5,741 | $43 |
| Destruction and/or removal of large growth of bladder using an endoscope | 14 | $5,527 | $345 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $5,151 | $286 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 12 | $4,950 | $381 |
| Bcg (intravesical) per instillation | 11 | $4,765 | None |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $3,574 | $238 |
| Complicated insertion of bladder tube | 20 | $3,562 | $96 |
| Simple insertion of temporary bladder tube | 33 | $3,490 | $59 |
| Instillation of anti-cancer drug into bladder | 12 | $3,220 | $72 |
| Simple bladder irrigation and/or instillation | 27 | $3,209 | $70 |
| Biopsy of prostate gland | 14 | $2,784 | $199 |
| Short return visit | 66 | $2,761 | $38 |
| Insertion of stent in ureter using an endoscope | 19 | $2,747 | $119 |
| Urinalysis, manual test | 528 | $2,351 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 129 | $2,247 | $15 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $1,767 | $110 |
| Long return visit (40+ min) | 13 | $1,699 | $121 |
| Ultrasound scan of pelvic region through rectum | 18 | $1,611 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,545 | $110 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $1,294 | $29 |
| Ultrasonic guidance for needle placement | 13 | $680 | $52 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 25 | $638 | $26 |
| Injection of drug or substance under skin or into muscle | 14 | $256 | $17 |
| Electronic assessment of bladder emptying | 11 | $81 | $7 |
2017: 31 services
| New patient visit (45+ min) | 311 | $39,955 | $128 |
| Return visit (30+ min) | 312 | $30,025 | $85 |
| Diagnostic exam of bladder and urethra using an endoscope | 182 | $29,651 | $141 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 25 | $27,108 | None |
| Short return visit (20+ min) | 342 | $25,789 | $58 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 24 | $17,572 | $732 |
| New patient visit (30+ min) | 143 | $12,636 | $88 |
| Bcg (intravesical) per instillation | 18 | $8,755 | None |
| Limited ultrasound scan of pelvis | 179 | $8,185 | $42 |
| Complicated insertion of bladder tube | 16 | $7,538 | $111 |
| Instillation of anti-cancer drug into bladder | 18 | $6,702 | $80 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $6,101 | $277 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 14 | $5,483 | $366 |
| Biopsy of prostate gland | 24 | $4,933 | $206 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 15 | $4,739 | $316 |
| Insertion of temporary bladder tube | 89 | $4,350 | $42 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 16 | $4,027 | $212 |
| Urinalysis, manual test | 523 | $2,649 | $3 |
| Ultrasound scan of pelvic region through rectum | 25 | $2,294 | $92 |
| Insertion of device into abdomen with pressure and urine flow rate study | 21 | $2,255 | $107 |
| Insertion of stent in ureter using an endoscope | 12 | $2,046 | $120 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $2,024 | $30 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,889 | $118 |
| Short return visit | 46 | $1,878 | $37 |
| Ultrasound measurement of bladder capacity after voiding | 90 | $1,846 | $18 |
| Long return visit (40+ min) | 11 | $1,513 | $126 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 48 | $1,126 | $19 |
| Injection procedure to cause erection | 11 | $991 | $76 |
| Simple insertion of temporary bladder tube | 16 | $920 | $51 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 22 | $708 | $32 |
| Injection of drug or substance under skin or into muscle | 14 | $392 | $23 |
2016: 30 services
| New patient visit (45+ min) | 273 | $36,408 | $133 |
| Diagnostic exam of bladder and urethra using an endoscope | 169 | $34,954 | $175 |
| Return visit (30+ min) | 349 | $34,026 | $82 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $26,756 | None |
| Short return visit (20+ min) | 305 | $25,798 | $61 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $13,363 | $742 |
| Limited ultrasound scan of pelvis | 174 | $7,886 | $43 |
| Instillation of anti-cancer drug into bladder | 19 | $5,879 | $93 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 17 | $5,395 | $317 |
| Insertion of temporary bladder tube | 80 | $5,307 | $49 |
| Bcg (intravesical) per instillation | 16 | $5,229 | None |
| New patient visit (30+ min) | 53 | $4,540 | $86 |
| Complicated insertion of bladder tube | 11 | $4,071 | $113 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,983 | $362 |
| Biopsy of prostate gland | 16 | $2,916 | $182 |
| Urinalysis, manual test | 493 | $2,518 | $3 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 27 | $2,416 | $89 |
| Insertion of device into abdomen with pressure and urine flow rate study | 22 | $2,363 | $107 |
| Simple insertion of temporary bladder tube | 23 | $2,189 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,125 | $118 |
| Ultrasound scan of pelvic region through rectum | 21 | $1,849 | $88 |
| Long return visit (40+ min) | 11 | $1,692 | $130 |
| Insertion of stent in ureter using an endoscope | 11 | $1,665 | $139 |
| Short return visit | 31 | $1,363 | $39 |
| Ultrasound measurement of bladder capacity after voiding | 61 | $1,181 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $1,041 | $29 |
| Ultrasonic guidance for needle placement | 14 | $761 | $54 |
| Injection of drug or substance under skin or into muscle | 16 | $584 | $23 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $434 | $19 |
| Electronic assessment of bladder emptying | 11 | $74 | $7 |
2015: 30 services
| Return visit (30+ min) | 370 | $38,065 | $87 |
| Diagnostic exam of bladder and urethra using an endoscope | 144 | $32,040 | $181 |
| New patient visit (45+ min) | 225 | $29,981 | $133 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $26,054 | None |
| Short return visit (20+ min) | 285 | $21,412 | $58 |
| Ct scan of abdomen and pelvis before and after contrast | 45 | $11,240 | $250 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 14 | $10,257 | $733 |
| Instillation of anti-cancer drug into bladder | 14 | $8,360 | $97 |
| Bcg (intravesical) per instillation | 13 | $7,177 | None |
| Limited ultrasound scan of pelvis | 152 | $6,984 | $43 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 21 | $6,736 | $321 |
| Insertion of temporary bladder tube | 90 | $6,014 | $49 |
| New patient visit (30+ min) | 48 | $4,210 | $88 |
| Ct scan of abdomen and pelvis with contrast | 16 | $3,423 | $214 |
| Biopsy of prostate gland | 16 | $3,182 | $199 |
| Urinalysis, manual test | 560 | $2,997 | $3 |
| Simple insertion of temporary bladder tube | 12 | $2,468 | $63 |
| Insertion of device into abdomen with pressure and urine flow rate study | 22 | $2,365 | $108 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 25 | $2,289 | $92 |
| Ct scan of chest with contrast | 18 | $2,164 | $114 |
| Long return visit (40+ min) | 17 | $1,969 | $116 |
| Insertion of stent in ureter using an endoscope | 11 | $1,708 | $142 |
| Ultrasound measurement of bladder capacity after voiding | 74 | $1,555 | $18 |
| Short return visit | 39 | $1,542 | $38 |
| Ultrasound scan of pelvic region through rectum | 18 | $1,518 | $84 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $975 | $31 |
| Ultrasonic guidance for needle placement | 15 | $791 | $53 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $377 | $18 |
| Electronic assessment of bladder emptying | 26 | $206 | $8 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 68 | $9 | $0 |
2014: 34 services
| Return visit (30+ min) | 390 | $38,364 | $86 |
| New patient visit (45+ min) | 240 | $32,812 | $137 |
| Diagnostic exam of bladder and urethra using an endoscope | 155 | $32,383 | $178 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 25 | $30,812 | None |
| Short return visit (20+ min) | 326 | $24,110 | $57 |
| Ct scan of abdomen and pelvis before and after contrast | 47 | $12,699 | $270 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 30 | $9,884 | $319 |
| Insertion of temporary bladder tube | 120 | $7,264 | $47 |
| Instillation of anti-cancer drug into bladder | 13 | $6,819 | $95 |
| Limited ultrasound scan of pelvis | 119 | $6,382 | $49 |
| Bcg (intravesical) per instillation | 12 | $6,108 | None |
| Biopsy of prostate gland | 31 | $6,081 | $196 |
| Insertion of device into abdomen with pressure and urine flow rate study | 42 | $4,497 | $105 |
| Ct scan of abdomen and pelvis with contrast | 22 | $4,489 | $204 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 42 | $4,011 | $93 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 16 | $3,978 | $234 |
| Urinalysis, manual test | 662 | $3,309 | $3 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 11 | $3,254 | $296 |
| Simple insertion of temporary bladder tube | 23 | $3,135 | $61 |
| New patient visit (30+ min) | 31 | $2,779 | $90 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 12 | $2,687 | $192 |
| Ultrasound scan of pelvic region through rectum | 31 | $2,659 | $86 |
| Insertion of stent in ureter using an endoscope | 15 | $2,427 | $128 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,233 | $118 |
| Ultrasonic guidance for needle placement | 31 | $2,125 | $69 |
| Injection procedure to cause erection | 14 | $2,023 | $72 |
| Long return visit (40+ min) | 15 | $1,804 | $120 |
| Ct scan of chest with contrast | 16 | $1,797 | $112 |
| Ultrasound measurement of bladder capacity after voiding | 84 | $1,659 | $17 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $1,209 | $30 |
| Short return visit | 28 | $1,136 | $36 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $566 | $18 |
| Electronic assessment of bladder emptying | 27 | $199 | $7 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 76 | $11 | $0 |
2013: 32 services
| Return visit (30+ min) | 404 | $37,171 | $83 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $36,071 | None |
| New patient visit (45+ min) | 244 | $31,806 | $130 |
| Short return visit (20+ min) | 396 | $30,498 | $60 |
| Diagnostic exam of bladder and urethra using an endoscope | 128 | $26,231 | $176 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $12,631 | $702 |
| Ct scan of abdomen and pelvis before and after contrast | 33 | $10,377 | $305 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 24 | $7,528 | $314 |
| Insertion of temporary bladder tube | 121 | $7,425 | $50 |
| Limited ultrasound scan of pelvis | 87 | $7,198 | $77 |
| Ct scan of abdomen and pelvis with contrast | 21 | $5,348 | $255 |
| Ultrasonic guidance for needle placement | 25 | $4,826 | $193 |
| Biopsy of prostate gland | 24 | $4,496 | $187 |
| New patient visit (30+ min) | 46 | $4,097 | $89 |
| Simple insertion of temporary bladder tube | 24 | $3,903 | $62 |
| Crushing of stone of ureter using an endoscope | 11 | $3,470 | $315 |
| Urinalysis, manual test | 701 | $3,339 | $3 |
| Insertion of device into abdomen with pressure and urine flow rate study | 28 | $2,907 | $104 |
| Insertion of stent in ureter using an endoscope | 19 | $2,459 | $112 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 30 | $2,435 | $81 |
| Ct scan of chest with contrast | 18 | $2,324 | $129 |
| Ultrasound measurement of bladder capacity after voiding | 110 | $2,205 | $18 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,940 | $114 |
| Short return visit | 52 | $1,906 | $35 |
| Ultrasound scan of pelvic region through rectum | 29 | $1,887 | $65 |
| Ct scan of abdomen and pelvis without contrast | 11 | $1,452 | $121 |
| Injection procedure to cause erection | 14 | $1,355 | $75 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $1,337 | $30 |
| Injection of drug or substance under skin or into muscle | 12 | $879 | $22 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $586 | $17 |
| Electronic assessment of bladder emptying | 13 | $92 | $7 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 63 | $8 | $0 |
Medicaid work
$4,186 in 2024
Medicaid paid $4,186 for 65 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (45+ min) | 27 | $2,172 |
| Return visit (30+ min) | 38 | $2,014 |
| 2024 | 65 | 2 | 14 | $4,186 |
| 2023 | 44 | 2 | 15 | $603 |
| 2022 | 15 | 1 | 14 | $40 |
| 2021 | 24 | 2 | 12 | $2,503 |
| 2020 | 40 | 1 | 13 | $104 |
| 2019 | 13 | 1 | 13 | $2,609 |
| 2018 | 14 | 1 | 14 | $2,711 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 15 | $519 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 29 | $84 |
2022
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 15 | $40 |
2021
| Clinic visit/encounter, all-inclusive | 12 | $2,503 |
| Short return visit | 12 | $0 |
2020
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 40 | $104 |
2019
| Clinic visit/encounter, all-inclusive | 13 | $2,609 |
2018
| Clinic visit/encounter, all-inclusive | 14 | $2,711 |
Drugs they prescribed that Part D paid
$82,359
Pharmacies billed $82,359 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (34 of 894) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
809 generic and 85 brand-name prescriptions · $82,359 in drug cost · 220 antibiotic prescriptions to 160 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 47 | $35,439 | $754 |
| Gemtesa | 31 | $27,095 | $874 |
| Tamsulosin | 233 | $4,164 | $18 |
| Testosterone | 24 | $1,706 | $71 |
| Potassium Citrate Er | 16 | $1,400 | $87 |
See all 15 drugs
| Myrbetriq | 47 | $35,439 | $754 |
| Gemtesa | 31 | $27,095 | $874 |
| Tamsulosin | 233 | $4,164 | $18 |
| Testosterone | 24 | $1,706 | $71 |
| Potassium Citrate Er | 16 | $1,400 | $87 |
| Finasteride | 104 | $1,235 | $12 |
| Nitrofurantoin | 25 | $1,016 | $41 |
| Trospium Chloride | 18 | $740 | $41 |
| Oxybutynin Chloride Er | 18 | $636 | $35 |
| Sulfamethoxazole-Trimethoprim | 68 | $613 | $9 |
| Ciprofloxacin | 89 | $302 | $3 |
| Bicalutamide | 13 | $197 | $15 |
| Hydrocodone-Acetaminophen | 30 | $184 | $6 |
| Alfuzosin Hcl Er | 14 | $138 | $10 |
| Alprazolam | 45 | $79 | $2 |
Year by year
| 2024 | 894 | 411 | 4% (34) | 10% | $82,359 |
| 2023 | 987 | 415 | 3% (29) | 9% | $62,831 |
| 2022 | 943 | 404 | 3% (25) | 5% | $56,182 |
| 2021 | 1,117 | 450 | 1% (15) | 14% | $119,332 |
| 2020 | 1,696 | 517 | 2% (30) | 10% | $159,476 |
| 2019 | 1,656 | 486 | 1% (23) | None | $135,676 |
| 2018 | 2,015 | 515 | 2% (46) | None | $208,271 |
| 2017 | 1,976 | 483 | 2% (42) | 19% | $202,067 |
| 2016 | 1,784 | 404 | 2% (33) | None | $151,630 |
| 2015 | 1,731 | 399 | 2% (29) | None | $131,612 |
| 2014 | 1,726 | 381 | 2% (26) | None | $110,635 |
| 2013 | 1,620 | 370 | 2% (38) | None | $102,663 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Myrbetriq | 43 | $28,023 | $652 |
| Gemtesa | 16 | $9,037 | $565 |
| Tamsulosin | 326 | $8,585 | $26 |
| Nitrofurantoin | 37 | $2,516 | $68 |
| Finasteride | 112 | $2,069 | $18 |
| Testosterone | 14 | $1,144 | $82 |
| Oxybutynin Chloride Er | 29 | $1,096 | $38 |
| Sulfamethoxazole-Trimethoprim | 80 | $1,022 | $13 |
| Alfuzosin Hcl Er | 19 | $512 | $27 |
| Ciprofloxacin | 85 | $354 | $4 |
| Bicalutamide | 11 | $226 | $21 |
| Nitrofurantoin Mono-Macro | 11 | $208 | $19 |
| Hydrocodone-Acetaminophen | 21 | $145 | $7 |
| Amoxicillin-Clavulanate Potass | 12 | $134 | $11 |
| Amoxicillin | 11 | $54 | $5 |
| Alprazolam | 45 | $30 | $1 |
2022: 14 drugs
| Myrbetriq | 26 | $26,281 | $1,011 |
| Tamsulosin | 334 | $6,769 | $20 |
| Testosterone | 11 | $3,649 | $332 |
| Finasteride | 118 | $2,434 | $21 |
| Nitrofurantoin | 29 | $2,340 | $81 |
| Oxybutynin Chloride Er | 33 | $1,712 | $52 |
| Sulfamethoxazole-Trimethoprim | 81 | $716 | $9 |
| Bicalutamide | 22 | $654 | $30 |
| Dutasteride | 12 | $595 | $50 |
| Trospium Chloride | 11 | $419 | $38 |
| Ciprofloxacin | 83 | $338 | $4 |
| Nitrofurantoin Mono-Macro | 13 | $252 | $19 |
| Hydrocodone-Acetaminophen | 19 | $100 | $5 |
| Alprazolam | 36 | $53 | $1 |
2021: 14 drugs
| Myrbetriq | 109 | $82,810 | $760 |
| Tamsulosin | 411 | $9,043 | $22 |
| Finasteride | 216 | $5,767 | $27 |
| Nitrofurantoin | 40 | $4,096 | $102 |
| Potassium Citrate Er | 17 | $2,151 | $127 |
| Oxybutynin Chloride Er | 34 | $1,694 | $50 |
| Dutasteride | 11 | $809 | $74 |
| Bicalutamide | 17 | $534 | $31 |
| Alfuzosin Hcl Er | 12 | $384 | $32 |
| Sulfamethoxazole-Trimethoprim | 45 | $336 | $7 |
| Ciprofloxacin | 54 | $282 | $5 |
| Terazosin | 15 | $272 | $18 |
| Trimethoprim | 11 | $261 | $24 |
| Hydrocodone-Acetaminophen | 12 | $93 | $8 |
2020: 19 drugs
| Myrbetriq | 89 | $78,428 | $881 |
| Testosterone | 29 | $18,716 | $645 |
| Tamsulosin | 629 | $13,935 | $22 |
| Finasteride | 320 | $8,668 | $27 |
| Nitrofurantoin | 78 | $7,451 | $96 |
| Potassium Citrate Er | 30 | $4,135 | $138 |
| Oxybutynin Chloride Er | 41 | $2,709 | $66 |
| Testosterone Cypionate | 25 | $1,553 | $62 |
| Dutasteride | 16 | $1,439 | $90 |
| Alfuzosin Hcl Er | 30 | $1,196 | $40 |
| Bicalutamide | 21 | $1,008 | $48 |
| Sulfamethoxazole-Trimethoprim | 70 | $697 | $10 |
| Terazosin | 29 | $533 | $18 |
| Doxycycline Monohydrate | 17 | $342 | $20 |
| Ciprofloxacin | 83 | $329 | $4 |
| Trimethoprim | 12 | $320 | $27 |
| Nitrofurantoin Mono-Macro | 13 | $255 | $20 |
| Hydrocodone-Acetaminophen | 25 | $144 | $6 |
| Cephalexin | 14 | $129 | $9 |
2019: 23 drugs
| Myrbetriq | 81 | $52,133 | $644 |
| Tamsulosin | 637 | $14,930 | $23 |
| Finasteride | 296 | $9,097 | $31 |
| Testosterone | 12 | $8,282 | $690 |
| Toviaz | 17 | $7,389 | $435 |
| Potassium Citrate Er | 29 | $6,286 | $217 |
| Nitrofurantoin | 52 | $4,683 | $90 |
| Silodosin | 24 | $3,992 | $166 |
| Oxybutynin Chloride Er | 41 | $2,267 | $55 |
| Dutasteride | 16 | $1,416 | $89 |
| Testosterone Cypionate | 25 | $1,413 | $57 |
| Bicalutamide | 35 | $1,115 | $32 |
| Terazosin | 35 | $1,109 | $32 |
| Alfuzosin Hcl Er | 33 | $803 | $24 |
| Oxybutynin Chloride | 25 | $513 | $21 |
| Imipramine | 22 | $463 | $21 |
| Sulfamethoxazole-Trimethoprim | 60 | $349 | $6 |
| Nitrofurantoin Mono-Macro | 12 | $301 | $25 |
| Cephalexin | 11 | $270 | $25 |
| Ciprofloxacin | 51 | $262 | $5 |
| Trimethoprim | 13 | $228 | $18 |
| Levofloxacin | 15 | $135 | $9 |
| Hydrocodone-Acetaminophen | 20 | $100 | $5 |
2018: 25 drugs
| Myrbetriq | 111 | $63,717 | $574 |
| Rapaflo | 57 | $21,247 | $373 |
| Androgel | 21 | $19,190 | $914 |
| Tamsulosin | 673 | $18,869 | $28 |
| Toviaz | 27 | $11,548 | $428 |
| Finasteride | 351 | $8,894 | $25 |
| Cialis | 16 | $7,646 | $478 |
| Potassium Citrate Er | 30 | $7,255 | $242 |
| Vesicare | 11 | $5,902 | $537 |
| Nitrofurantoin | 72 | $5,632 | $78 |
| Oxybutynin Chloride Er | 59 | $3,264 | $55 |
| Terazosin | 29 | $902 | $31 |
| Doxazosin Mesylate | 20 | $852 | $43 |
| Alfuzosin Hcl Er | 21 | $705 | $34 |
| Cephalexin | 44 | $631 | $14 |
| Oxybutynin Chloride | 34 | $579 | $17 |
| Bicalutamide | 27 | $560 | $21 |
| Ciprofloxacin | 104 | $543 | $5 |
| Nitrofurantoin Mono-Macro | 19 | $449 | $24 |
| Trimethoprim | 25 | $420 | $17 |
| Sulfamethoxazole-Trimethoprim | 60 | $413 | $7 |
| Testosterone Cypionate | 11 | $409 | $37 |
| Imipramine | 19 | $308 | $16 |
| Hydrocodone-Acetaminophen | 39 | $176 | $5 |
| Levofloxacin | 13 | $80 | $6 |
2017: 24 drugs
| Myrbetriq | 129 | $61,985 | $481 |
| Tamsulosin | 643 | $19,930 | $31 |
| Botox | 19 | $15,849 | $834 |
| Rapaflo | 46 | $15,827 | $344 |
| Cialis | 26 | $15,195 | $584 |
| Androgel | 15 | $11,594 | $773 |
| Finasteride | 353 | $8,057 | $23 |
| Potassium Citrate Er | 24 | $8,026 | $334 |
| Nitrofurantoin | 89 | $5,626 | $63 |
| Tolterodine Tartrate Er | 14 | $3,800 | $271 |
| Oxybutynin Chloride Er | 54 | $3,294 | $61 |
| Terazosin | 57 | $1,148 | $20 |
| Doxazosin Mesylate | 17 | $765 | $45 |
| Sulfamethoxazole-Trimethoprim | 76 | $756 | $10 |
| Oxybutynin Chloride | 25 | $737 | $29 |
| Cephalexin | 43 | $696 | $16 |
| Trimethoprim | 27 | $655 | $24 |
| Alfuzosin Hcl Er | 26 | $499 | $19 |
| Ciprofloxacin | 87 | $457 | $5 |
| Nitrofurantoin Mono-Macro | 13 | $330 | $25 |
| Bicalutamide | 20 | $255 | $13 |
| Imipramine | 15 | $220 | $15 |
| Oxycodone-Acetaminophen | 14 | $100 | $7 |
| Hydrocodone-Acetaminophen | 21 | $77 | $4 |
2016: 23 drugs
| Myrbetriq | 72 | $31,997 | $444 |
| Tamsulosin | 586 | $16,171 | $28 |
| Androgel | 17 | $14,206 | $836 |
| Cialis | 31 | $12,683 | $409 |
| Rapaflo | 32 | $8,852 | $277 |
| Finasteride | 273 | $7,148 | $26 |
| Toviaz | 18 | $6,369 | $354 |
| Potassium Citrate Er | 21 | $6,323 | $301 |
| Oxybutynin Chloride Er | 91 | $5,476 | $60 |
| Nitrofurantoin | 90 | $5,229 | $58 |
| Terazosin | 55 | $867 | $16 |
| Cephalexin | 56 | $841 | $15 |
| Oxybutynin Chloride | 22 | $725 | $33 |
| Doxazosin Mesylate | 19 | $715 | $38 |
| Bicalutamide | 42 | $610 | $15 |
| Trimethoprim | 22 | $558 | $25 |
| Ciprofloxacin | 90 | $522 | $6 |
| Sulfamethoxazole-Trimethoprim | 35 | $382 | $11 |
| Nitrofurantoin Mono-Macro | 15 | $334 | $22 |
| Hydrocodone-Acetaminophen | 29 | $259 | $9 |
| Imipramine | 18 | $209 | $12 |
| Testosterone Cypionate | 11 | $198 | $18 |
| Ampicillin Trihydrate | 14 | $88 | $6 |
2015: 23 drugs
| Myrbetriq | 48 | $18,677 | $389 |
| Tamsulosin | 523 | $16,512 | $32 |
| Vesicare | 28 | $10,100 | $361 |
| Cialis | 36 | $10,011 | $278 |
| Androgel | 11 | $9,165 | $833 |
| Oxybutynin Chloride Er | 134 | $8,702 | $65 |
| Potassium Citrate Er | 19 | $4,995 | $263 |
| Finasteride | 240 | $4,796 | $20 |
| Testosterone | 14 | $4,470 | $319 |
| Nitrofurantoin | 113 | $4,114 | $36 |
| Rapaflo | 17 | $4,054 | $238 |
| Testosterone Cypionate | 24 | $1,124 | $47 |
| Bicalutamide | 38 | $1,023 | $27 |
| Terazosin | 62 | $818 | $13 |
| Trimethoprim | 33 | $737 | $22 |
| Doxazosin Mesylate | 16 | $632 | $39 |
| Oxybutynin Chloride | 26 | $603 | $23 |
| Nitrofurantoin Mono-Macro | 16 | $472 | $30 |
| Ciprofloxacin | 81 | $394 | $5 |
| Imipramine | 16 | $380 | $24 |
| Cephalexin | 46 | $329 | $7 |
| Sulfamethoxazole-Trimethoprim | 49 | $305 | $6 |
| Hydrocodone-Acetaminophen | 22 | $156 | $7 |
2014: 20 drugs
| Vesicare | 65 | $22,561 | $347 |
| Tamsulosin | 528 | $11,531 | $22 |
| Oxybutynin Chloride Er | 146 | $10,486 | $72 |
| Finasteride | 239 | $5,526 | $23 |
| Flomax | 17 | $4,904 | $288 |
| Tolterodine Tartrate Er | 19 | $4,106 | $216 |
| Nitrofurantoin | 80 | $3,310 | $41 |
| Potassium Citrate Er | 15 | $3,169 | $211 |
| Terazosin | 84 | $1,347 | $16 |
| Doxazosin Mesylate | 21 | $887 | $42 |
| Trimethoprim | 44 | $867 | $20 |
| Testosterone Cypionate | 20 | $827 | $41 |
| Sulfamethoxazole-Trimethoprim | 79 | $775 | $10 |
| Oxybutynin Chloride | 16 | $654 | $41 |
| Nitrofurantoin Mono-Macro | 15 | $652 | $43 |
| Ciprofloxacin | 86 | $404 | $5 |
| Cephalexin | 38 | $292 | $8 |
| Imipramine | 20 | $246 | $12 |
| Hydrocodone-Acetaminophen | 18 | $205 | $11 |
| Fluconazole | 11 | $50 | $5 |
2013: 23 drugs
| Vesicare | 60 | $17,407 | $290 |
| Oxybutynin Chloride Er | 118 | $10,416 | $88 |
| Tamsulosin | 454 | $10,232 | $23 |
| Finasteride | 233 | $7,845 | $34 |
| Detrol La | 20 | $7,836 | $392 |
| Nitrofurantoin | 76 | $4,616 | $61 |
| Enablex | 15 | $4,115 | $274 |
| Toviaz | 11 | $3,990 | $363 |
| Trospium Chloride | 34 | $3,818 | $112 |
| Flomax | 14 | $2,567 | $183 |
| Terazosin | 100 | $1,653 | $17 |
| Bicalutamide | 37 | $1,372 | $37 |
| Nitrofurantoin Mono-Macro | 19 | $1,108 | $58 |
| Trimethoprim | 36 | $966 | $27 |
| Alfuzosin | 16 | $732 | $46 |
| Sulfamethoxazole-Trimethoprim | 77 | $671 | $9 |
| Testosterone Cypionate | 13 | $461 | $35 |
| Ciprofloxacin | 72 | $332 | $5 |
| Cephalexin | 41 | $266 | $6 |
| Doxazosin Mesylate | 15 | $258 | $17 |
| Hydrocodone-Acetaminophen | 29 | $206 | $7 |
| Oxybutynin Chloride | 13 | $198 | $15 |
| Hydrochlorothiazide | 12 | $61 | $5 |
Money from drug and device companies
$1,124 in 2025
| 2025 | 16 | 34 | None | $1,124 |
| 2024 | 20 | 47 | None | $1,581 |
| 2023 | 15 | 58 | None | $1,532 |
| 2022 | 15 | 29 | None | $735 |
| 2021 | 13 | 22 | None | $433 |
| 2020 | 5 | 10 | None | $258 |
| 2019 | 11 | 22 | None | $445 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $250 | 8 payments
|
| Progenics Pharmaceuticals | Pylarify | $138 | 3 payments
|
| Janssen Biotech | Erleada | $100 | 3 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $85 | 3 payments
|
| Abbvie | Botox | $80 | 4 payments
|
| Profound Medical | Tulsa-Pro | $71 | 1 payment
|
See all 34 published payments
| Boston Scientific | Meals · 2025-12-16 | Spaceoar Vue System - 10ml | $49 |
| Janssen Biotech | Meals · 2025-12-15 | Erleada | $46 |
| Abbvie | Meals · 2025-12-09 | Lupron Depot | $14 |
| Pfizer | Meals · 2025-12-03 | Xtandi | $25 |
| Urogen Pharma | Meals · 2025-11-20 | Zusduri | $24 |
| Davol | Meals · 2025-10-08 | Arista | $38 |
| Sumitomo Pharma America | Meals · 2025-10-07 | Gemtesa | $43 |
| Procept Biorobotics | Meals · 2025-10-01 | Aquabeam Robotic System | $26 |
| Abbvie | Meals · 2025-09-23 | Lupron Depot | $23 |
| Sumitomo Pharma America | Meals · 2025-08-28 | Orgovyx | $22 |
| Janssen Biotech | Meals · 2025-08-20 | Erleada | $36 |
| Sumitomo Pharma America | Meals · 2025-08-12 | Gemtesa | $35 |
| Ferring Pharmaceuticals | Meals · 2025-07-30 | Adstiladrin | $33 |
| Telix Pharmaceuticals | Meals · 2025-06-25 | Illuccix | $23 |
| Ethicon US | Meals · 2025-06-11 | Stratafix | $22 |
| Telix Pharmaceuticals | Meals · 2025-05-27 | Illuccix | $27 |
| Smith+Nephew | Meals · 2025-05-22 | Stravix | $31 |
| Progenics Pharmaceuticals | Meals · 2025-05-22 | Pylarify | $100 |
| Sumitomo Pharma America | Meals · 2025-05-09 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-05-01 | Gemtesa | $2 |
| Sumitomo Pharma America | Meals · 2025-04-30 | Gemtesa | $41 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $24 |
| Progenics Pharmaceuticals | Meals · 2025-04-17 | Pylarify | $13 |
| C. R. Bard Inc. & Subsidiaries | Meals · 2025-04-10 | Bard Urinary Drainage Bag | $38 |
| Progenics Pharmaceuticals | Meals · 2025-03-19 | Pylarify | $26 |
| Abbvie | Meals · 2025-03-18 | Botox | $20 |
| Sumitomo Pharma America | Meals · 2025-03-04 | Gemtesa | $36 |
| Ferring Pharmaceuticals | Meals · 2025-02-26 | Adstiladrin | $29 |
| Janssen Biotech | Meals · 2025-02-19 | Erleada | $18 |
| Olympus America | Meals · 2025-02-13 | Itind System | $61 |
| Profound Medical | Meals · 2025-02-12 | Tulsa-Pro | $71 |
| Sumitomo Pharma America | Meals · 2025-02-03 | Gemtesa | $35 |
| Abbvie | Meals · 2025-01-24 | Botox | $22 |
| Urogen Pharma | Meals · 2025-01-13 | Jelmyto | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,581
| Sumitomo Pharma America | Gemtesa | $217 | 7 payments
|
| Abbvie | Botox | $195 | 9 payments
|
| Axonics | Axonics | $168 | 3 payments
|
| Telix Pharmaceuticals | Illuccix | $149 | 2 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $144 | 2 payments
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $121 | 1 payment
|
| Ambu | None | $79 | 2 payments
|
| Becton Dickinson and | Bard Urinary Drainage Bag | $76 | 3 payments
|
| Pfizer | Xtandi | $60 | 3 payments
|
| ConvaTec | Gentlecath Glide | $56 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam System | $54 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $53 | 2 payments
|
| Boston Scientific | Rezum Generator | $33 | 2 payments
|
| Immunitybio | Anktiva | $31 | 1 payment
|
| Urogen Pharma | Jelmyto | $31 | 1 payment
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $30 | 1 payment
|
| Myriad Genetic Laboratories | Prolaris | $24 | 1 payment
|
| Accord Healthcare | Camcevi | $24 | 1 payment
|
| Coloplast | Porges Coloplast | $21 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $16 | 1 payment
|
2023: $1,532
| Sumitomo Pharma America | Gemtesa | $489 | 16 payments
|
| AbbVie | Botox | $168 | 8 payments
|
| Astellas Pharma US | Myrbetriq | $150 | 6 payments
|
| Boston Scientific | Rezum Generator | $133 | 4 payments
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $117 | 5 payments
|
| Blue Earth Diagnostics | Posluma | $109 | 6 payments
|
| Edap Technomed | None | $100 | 1 payment
|
| Tolmar | Eligard | $59 | 2 payments
|
| Pfizer | Xtandi | $53 | 3 payments
|
| UroGen Pharma | Jelmyto | $38 | 1 payment
|
| Antares Pharma | Nocdurna | $38 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $26 | 1 payment
|
| Teleflex | Urolift | $21 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $17 | 1 payment
|
| AngioDynamics | Nanoknife | $15 | 1 payment
|
2022: $735
| Astellas Pharma US | Myrbetriq | $168 | 4 payments
|
| Rochester Medical | None | $98 | 5 payments
|
| UroGen Pharma | Jelmyto | $70 | 2 payments
|
| Blue Earth Diagnostics | Axumin | $64 | 3 payments
|
| Abbvie | Lupron Depot | $59 | 3 payments
|
| Myriad Genetic Laboratories | Prolaris | $47 | 2 payments
|
| Sagent Pharmaceuticals | Glydo | $35 | 2 payments
|
| C. R. Bard Inc. & Subsidiaries | None | $34 | 1 payment
|
| Boston Scientific | General - Kidney Stone Disease | $29 | 1 payment
|
| Palette Life Sciences | None | $28 | 1 payment
|
| Janssen Biotech | Erleada | $24 | 1 payment
|
| Myovant Sciences | Orgovyx | $23 | 1 payment
|
| Teleflex | Urolift System | $21 | 1 payment
|
| Allergan | Botox | $17 | 1 payment
|
| Olympus America | Itind System | $15 | 1 payment
|
2021: $433
| AbbVie | Lupron Depot | $77 | 3 payments
|
| Boston Scientific | Lithovue | $72 | 3 payments
|
| Rochester Medical | None | $63 | 4 payments
|
| Ambu | None | $36 | 1 payment
|
| Allergan | Botox | $34 | 2 payments
|
| Ethicon US | Enseal X1 | $26 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $22 | 1 payment
|
| Abbott Laboratories | Proclaim Ipg | $21 | 1 payment
|
| AngioDynamics | Nanoknife | $19 | 1 payment
|
| Axonics | Axonics R-Snm System | $18 | 1 payment
|
| Coloplast | Titan | $16 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $16 | 1 payment
|
| Urogen Pharma | Jelmyto | $14 | 1 payment
|
2020: $258
| Rochester Medical | None | $138 | 5 payments
|
| AbbVie | Lupron Depot | $42 | 2 payments
|
| Janssen Biotech | Erleada | $32 | 1 payment
|
| Amgen | Evenity | $25 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $21 | 1 payment
|
2019: $445
| Boston Scientific | Rezum | $98 | 4 payments
|
| AbbVie | Lupron Depot | $68 | 3 payments
|
| Allergan | Botox | $58 | 3 payments
|
| C. R. Bard Inc. & Subsidiaries | None | $39 | 2 payments
|
| NeoTract | Urolift | $38 | 2 payments
|
| Rochester Medical | None | $36 | 2 payments
|
| Astellas Pharma US | Xtandi | $32 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $23 | 1 payment
|
| Janssen Biotech | Zytiga | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $20 | 1 payment
|
| Sanofi Pasteur | Adacel | $14 | 1 payment
|
Professional record
- NPI
- 1891713418
- Licence
- CA G78346California G78346: Current · expires 2028-02-29
- Trained
- University of California, San Francisco School of Medicine, 1989 · 37 years ago
- Group
- Marin Community Clinic · Regents Univ of California UCSF
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 1000 S. Eliseo Dr, Suite #201, Greenbrae, CA, 94904
- NPI first listed
- 2006-07-18
- NPI last updated
- 2010-07-13
This is when the NPI record was last certified, not a medical board exam.